Adjuvant N Acetylcysteine for Post Traumatuic Stress Disorder

Phase 2

Completed

• Conditions: post traumatic stress disorder; Mental Health - Other mental health disorders

• Registration Number: ACTRN12618001784202
• Lead Sponsor: Austin Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-10-31
• Study Completion: 2021-11-11
• Last Update Posted: 12 September 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 105

Inclusion Criteria

To be considered for inclusion in this study, participants are required to be aged 18 or over; have the capacity to consent to the study and to follow its instructions and procedures; fulfil the DSM-5 diagnostic criteria for current PTSD (identified with the CAPS-5 monthly version); have completed a course of either trauma-focussed psychotherapy or an antidepressant; and if currently treated with an antidepressant the dose must have been stable for at least 2 weeks.

Exclusion Criteria

Participants are ineligible to enter the trial if they have a psychotic illness; known or suspected clinically unstable systemic medical disorder; epilepsy, recent gastrointestinal ulcers; currently use N-acetylcysteine, selenium or Vitamin E; a history of anaphylactic reaction to N-acetylcysteine . Female patients cannot be pregnant or lactating, and all participants must agree to using adequate contraception during the trial.

Study & Design

• Study Type: Interventional
• Study Design: Not specified